Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia

Abstract

Lurasidone was found to be non-inferior to risperidone on the primary endpoint with minimal effects on weight, metabolic parameters, or prolactin levels.